WuXi XDC Partners with Multitude Therapeutics and Signs MOU with Shanghai Huilian to Advance ADC Technologies
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
CRO / CMO / CDMO
Lonza Announces Factory Closures in the US and China Amid Global Network Optimization
Swiss Contract Manufacturing Organization (CMO) Lonza has released its 2023 financial report, which includes plans...
China-Based Biotechs Respond to US House Bill Limiting Federal Funding for ‘Concerning’ Companies
A bipartisan bill introduced on January 26, 2024, by members of the US House Select...
WuXi Biologics Launches WuXiaADCC PLUS Platform for Non-Fucosylated Antibody Development
WuXi Biologics (HKG: 2269), a Contract Research, Development, and Manufacturing Organization (CRDMO) based in China,...
Jiuzhou Pharmaceutical Expands with $42 Million Investment in Japanese CRO Services
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456), a Chinese pharmaceutical company, has declared plans to...
Shandong Province Launches Initiatives to Accelerate Pharmaceutical Innovation and Growth
Shandong province has announced a comprehensive set of measures aimed at optimizing review and approval...
Guangdong Aims to Boost Biomedicine Industry with Incentives and Strategic Development
The Guangdong Provincial Development and Reform Commission has unveiled an ambitious set of measures aimed...
WuXi Biologics’ Innovative Bispecific Platform WuXiBody Secures US Patent
WuXi Biologics (HKG: 2269), a leading China-based Contract Research, Development, and Manufacturing Organization (CRDMO), has...
WuXi Biologics Partners with BioNTech to Develop Next-Gen Antibodies in $20 Million Deal
WuXi Biologics (HKG: 2269), a China-based Contract Research, Development, and Manufacturing Organization (CRDMO), has entered...
WuXi Biologics Expands Manufacturing Capacity to 36,000 Liters at Worcester Facility
WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in...
Frontage Laboratories Expands European Footprint with Acquisition of Accelera’s DMPK Businesses
Frontage Laboratories Inc., (HKG: 1521), a Contract Research Organization (CRO) with operations in Pennsylvania, Suzhou,...
China Medical System Expands into Southeast Asia with Singapore Manufacturing Plant Lease
China Medical System Holdings Ltd (CMS, HKG: 0867) has announced that its joint venture, PharmaGend...
WuXi XDC and IntoCell Enter MOU to Advance Toxin Linker Technology and CRDMO Services
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
CATUG Biotechnology Partners with Carcell Biopharma to Advance Nucleic Acid Drug Development
CATUG Biotechnology (Suzhou) Co., Ltd, a Chinese biotechnology company, has entered into a partnership with...
Taiwan Bio and TRACT Therapeutics Forge Partnership to Combat Organ Rejection
Taiwan Bio Therapeutics Co., Ltd. has entered into a strategic partnership with U.S.-based TRACT Therapeutics,...
Biocytogen Pharmaceuticals Secures US Patent for Fully Human Antibody Mice Platform RenMab
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a China-based Contract Research Organization (CRO), has announced...
Suzhou Porton Biologics Partners with Asclepius Technology for NK Cell Project
China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd has entered into a...
VIVA Biotech Holdings Secures Nearly USD 210 Million in Financing Round
China-based Contract Research Organization (CRO) VIVA Biotech Holdings (HKG: 1873) has announced the completion of...
WuXi Biologics’ Subsidiary WuXi XDC Lists on Hong Kong Stock Exchange
WuXi Biologics (HKG: 2269) has successfully spun off its conjugate drug-focused subsidiary, WuXi XDC Cayman...
Hubei Topgene Biotechnology and Shanghai Genechem Partner on Drug Toxicological Safety and Clinical Research
Hubei Topgene Biotechnology Co., Ltd, a China-based biotechnology company, has entered into a partnership with...